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INTRODUCTION
This chapter makes treatment recommendations for adults
with biopsy-proven, idiopathic FSGS. The cost implications
for global application of this guideline are addressed in
Chapter 2.
6.1: Initial evaluation of FSGS
6.1.1: Undertake thorough evaluation to exclude
secondary forms of FSGS. (Not Graded)
6.1.2: Do not routinely perform genetic testing. (Not
Graded)
BACKGROUND
The classical description of FSGS includes segmental increase
of mesangial matrix with obliteration of the capillaries,
sclerosis, hyalinosis, foam cells, and segmental scarring, and
adhesion between the glomerular tuft and Bowman’s capsule.
A recently proposed pathology classification has pointed to
the existence of nonsclerotic forms of FSGS.152 There has
been a marked increase in the number of known underlying
causes for the lesion of FSGS over the last 10–20 years.
Perhaps a consequence of this has been that the incidence,
the age of onset, and the clinical presentation have also
dramatically altered over this timeframe. FSGS is now one of
the most common patterns of glomerular injury encountered
in human kidney biopsies,153,154 and it is the most common
cause of proteinuria in the African-American and US
Hispanic populations.
RATIONALE
K FSGS should be classified as idiopathic (primary) FSGS
or secondary FSGS. This is not merely semantic, but has
therapeutic implications. Idiopathic FSGS is defined by
exclusion of any other identifiable cause of secondary
FSGS.155 Secondary causes of FSGS are listed in Table 9,
and should be evaluated by detailed examination of the
patient, including medical history, physical examination,
family history, kidney imaging, and kidney pathology,
including electron micoscopy studies.156
K There are no good data to support genetic testing in
adults with FSGS, even in cases of steroid resistance. In
the absence of a family history of FSGS, mutations of
NPHS1 (nephrin), NPHS2 (podocin), alpha-actinin-4,
CD2AP, and TRPC-6 are detected in only 0–3% of
adults with FSGS.105,157–163 In addition, some patients
with a genetic abnormality have responded to therapy,
suggesting that the results of genetic analysis should not
change treatment decisions.
K African-Americans with FSGS are likely to have muta-
tions in the apolipoprotein L1 (APOL1) gene.164 Most
patients will present with non-nephrotic proteinuria. The
therapeutic implications of this mutation are currently
unknown, so this guideline does not suggest routine
testing for APOL1 mutations.
6.2: Initial treatment of FSGS
6.2.1: We recommend that corticosteroid and im-
munosuppressive therapy be considered only
in idiopathic FSGS associated with clinical
features of the nephrotic syndrome. (1C)
6.2.2: We suggest prednisone* be given at a daily
single dose of 1mg/kg (maximum 80mg) or
alternate-day dose of 2mg/kg (maximum
120mg). (2C)
6.2.3: We suggest the initial high dose of corticoster-
oids be given for a minimum of 4 weeks;
continue high-dose corticosteroids up to a
maximum of 16 weeks, as tolerated, or until
complete remission has been achieved, which-
ever is earlier. (2D)
6.2.4: We suggest corticosteroids be tapered slowly
over a period of 6 months after achieving
complete remission. (2D)
6.2.5: We suggest CNIs be considered as first-line
therapy for patients with relative contraindi-
cations or intolerance to high-dose cortico-
steroids (e.g., uncontrolled diabetes, psychia-
tric conditions, severe osteoporosis). (2D)
*Prednisone and prednisolone are equivalent, used in the same
dosage, and have both been used in RCTs depending on the country
of origin. All later references to prednisone in this chapter refer to
prednisone or prednisolone. All later references to oral corticoster-
oids refer to prednisone or prednisolone.
BACKGROUND
Patients with FSGS and persistent proteinuria are at increased
risk of progressive CKD and its accompanying cardiovascular
morbidity and mortality. Risks are dependent on the level
of proteinuria and kidney function.
The potential benefit of therapy includes disease cure,
control, and/or slowing the progression to ESRD. In FSGS,
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outcome parameters can be divided into kidney and protein-
uric events. Disease cure and control are defined primarily by
changes in proteinuria (see Table 10).
In most cases of idiopathic FSGS, the natural history of
the disease is prolonged, with even complete remitters having
a relapse rate of up to 40%. Those with partial remissions still
have a risk of slowly progressive loss of kidney function.
There is also a significant minority with no response to
therapy; hence, the potential benefits of treatment must be
constantly weighed against the risks of the chosen immuno-
suppressive therapy.13
Prognosis in patients with idiopathic FSGS is predicted by
the severity and persistence of proteinuria. Patients with non-
nephrotic proteinuria have a good prognosis, with kidney
survival rates of more than 95% after a mean follow-up of 6.5
to 9.3 years,165–167 even in older studies when few patients, if
any, were treated with RAS blockade. The conclusion still
seems to be valid, since a very recent study concluded that
even partial remission (reduction to non-nephrotic range
proteinuria) was associated with significant improvement in
kidney survival (80% vs. 40%) compared to no remission.103
Many observational studies have demonstrated that
remission of proteinuria, whether spontaneous or induced
by therapy, is associated with a good outcome.103,168–171
Many studies have shown, in univariate and multivariate
analyses, that development of a remission was associated with
prednisone treatment.103,172–174
The natural history of primary FSGS with nephrotic
syndrome is quite variable. Important predictors are the
magnitude of proteinuria, the level of kidney function, and
the amount of tubulo-interstitial injury.101,165,175 Resistance
to corticosteroids and immunosuppressive therapy is now
considered the strongest predictor of ESRD.166,176 Prognosis
is poor in patients who do not achieve remission, with 5-year
kidney survival averaging 65% (60–90%) and 10-year kidney
survival 30% (25–56%).165–167,177
RATIONALE
K Most patients that progress have persistent nephrotic-
range proteinuria; patients with non-nephrotic protein-
uria are at low risk for progressive kidney failure and
ESRD.
K Those with sustained non-nephrotic proteinuria are at
increased risk of cardiovascular morbidity and mortality.
Those risks should be managed, including treatment of
proteinuria with RAS blockade and control of blood
pressure.
K There is low-quality evidence to recommend cortico-
steroid or immunosuppressive therapy in primary FSGS
when accompanied by nephrotic syndrome.
K There is no evidence to suggest corticosteroid or
immunosuppressive therapy in secondary FSGS.
RAS Blockade and Blood Pressure Control
Optimal conservative management of patients with FSGS
should follow guidelines for patients with persistent protei-
nuria (see Chapter 2). RAS blockade should be routine;
however, it may be delayed in nephrotic syndrome to see if
there is a response to initial corticosteroid therapy. This is
particularly relevant if the nephrotic syndrome is severe, since
the risk of developing AKI due to hypoperfusion and acute
tubular necrosis (ATN) is increased in this setting.148,178
Table 9 | Causes of FSGS
Idiopathic (primary) FSGS
Secondary FSGS
1. Familial
a. Mutations in a-actinin 4
b. Mutations in NPHS1 (nephrin)
c. Mutations in NPHS2 (podocin)
d. Mutations in WT-1
e. Mutations in TRPC6
f. Mutations in SCARB2 (LIMP2)
g. Mutations in INF2 (formin)
h. Mutations in CD2-associated protein
i. Mitochondrial cytopathies
2. Virus associated
a. HIV-associated nephropathy
b. Parvovirus B19
3. Medication
a. Heroin-nephropathy
b. Interferon-a
c. Lithium
d. Pamidronate/alendronate
e. Anabolic steroids
4. Adaptive structural-functional responses likely mediated by
glomerular hypertrophy or hyperfiltration
4.1 Reduced kidney mass
a. Oligomeganephronia
b. Unilateral kidney agenesis
c. Kidney dysplasia
d. Cortical necrosis
e. Reflux nephropathy
f. Surgical kidney ablation
g. Chronic allograft nephropathy
h. Any advanced kidney disease with reduction in functioning
nephrons
4.2 Initially normal kidney mass
a. Diabetes mellitus
b. Hypertension
c. Obesity
d. Cyanotic congenital heart disease
e. Sickle cell anemia
5. Malignancy (lymphoma)
6. Nonspecific pattern of FSGS caused by kidney scarring in
glomerular disease
a. Focal proliferative glomerulonephritis (IgAN, LN,
pauci-immune focal necrotizing and crescentic GN)
b. Hereditary nephritis (Alport syndrome)
c. Membranous glomerulopathy
d. Thrombotic microangiopathy
FSGS, focal segmental glomerulosclerosis; GN, glomerulonephritis; HIV, Human
immunodeficiency virus; IgAN, immunoglobulin A nephropathy; LN, lupus nephritis.
Adapted from Deegens JK, Steenbergen EJ, Wetzels JF. Review on diagnosis and
treatment of focal segmental glomerulosclerosis. Neth J Med 2008; 66: 3–12 with
permission from Van Zuiden Communications B.V.;155 accessed http://www.
njmonline.nl/getpdf.php?t=a&id=10000260.
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Corticosteroids
Corticosteroid therapy should only be considered for patients
with idiopathic FSGS associated with nephrotic syndrome.
There are no data to support treatment with corticosteroids
in patients without nephrotic-range proteinuria and,
although there are no RCTs, there are numerous observa-
tional studies to support the use of corticosteroids in FSGS
when associated with nephrotic-range proteinuria.
Prior to 1985, idiopathic FSGS was considered a steroid-
resistant disease with poor outcome.165 In contrast, observa-
tional studies conducted after 1985 have reported better
outcomes and suggested that this improvement in response
was associated with a higher initial dose and longer duration
of treatment with corticosteroids.
Treatment routines have varied with durations from 4 to
24 months, and prednisone dosing from 0.3 to 1.5 mg/kg/d,
reported complete remission rates range from 28% to 74%,
and partial remission rates from 0% to 50%. The average
time to complete remission is 3–4 months, with a range up to
8 months.166,168,169,171
The timing of prednisone therapy initiation has been
debated. Spontaneous remissions do occur, with reported
rates varying from 5% to 23%. Spontaneous remissions are
more likely to occur in patients with tip lesions, with pre-
served kidney function, and lower grades of proteinuria.179
In such patients, prednisone treatment could be delayed
to see if spontaneous remission occurs with RAS blockade
and other conservative approaches, but no studies have
investigated this approach, or systematically analyzed its risks
and benefits.
In the absence of any evidence specific for FSGS, we
suggest that the guidelines for adult MCD are used to direct
further therapy in steroid-responsive primary FSGS (see
Chapter 5).
There is no evidence to support the use of corticosteroids
in secondary FSGS and, in current practice, such patients are
not treated with immunosuppressive therapy.180
Other Immunosuppressive Agents
Adult patients may tolerate poorly the sustained corticoster-
oid regimen recommended for primary FSGS, but there are
no RCTs to support the use of alternative immunosuppres-
sive agents as first-line therapy.
A retrospective observational study compared high-dose
oral prednisone (1 mg/kg/d) for at least 4 months and
tapering thereafter, with low-dose prednisone (0.5 mg/kg/d)
in combination with cyclosporine (3 mg/kg/d initial dose,
tapering to 50 mg/d) or azathioprine (2 mg/kg/d initial dose,
tapering to 0.5 mg/kg/d). Average duration of treatment was
20 months. Low-dose prednisone was given to 16 patients
with obesity, bone disease, or mild diabetes. Remission rates
were comparable; 63% for prednisone (n¼ 9), 80% for
prednisone plus azathioprine (n¼ 6), and 86% for predni-
sone plus cyclosporine (n¼ 10).172 Another study used
tacrolimus as initial therapy in six patients and noted a
remission in all.181
A randomized study in adult patients with FSGS
and persistent nephrotic syndrome after 6 months of RAS
blockade compared MMF (2 g/d for 6 months) plus low-
dose prednisone (0.5 mg/kg/d for 8–12 weeks) to high-
dose prednisone (1 mg/kg/d for 12–24 weeks, followed
by tapering over 8 weeks). Similar remission rates were
observed in the two regimens, 71% (12/17 patients) vs.
69% (11/16 patients).111 These limited data suggest that
patients who do not tolerate prolonged high-dose pred-
nisone might benefit from alternative immunosuppressive
agents, alone or in combination with a lower dose of
prednisone. A CNI is favored in view of the evidence derived
from studies in patients with steroid-resistant FSGS (see
below).
6.3: Treatment for relapse
6.3.1: We suggest that a relapse of nephrotic syn-
drome is treated as per the recommendations
for relapsing MCD in adults (see Chapters 5.1
and 5.2). (2D)
RATIONALE
K There is very low–quality evidence to guide treatment
of relapses in steroid-responsive FSGS. We suggest that
the guidelines for relapsing MCD are followed (see
Chapter 5.2).
Table 10 | Definitions of nephrotic syndrome in adults with FSGS
Classification Definition
Complete
remission
Reduction of proteinuria to o0.3 g/d or o300mg/g (o30mg/mmol), urine creatinine and normal serum creatinine and
serum albumin 43.5 g/dl (35 g/l)
Partial remissiona Reduction of proteinuria to 0.3–3.5 g/d (300–3500mg/g [30–350mg/mmol]), urine creatinine and stable serum creatinine
(change in creatinine o25%)
or
Reduction of proteinuria to 0.3–3.5 g/d (300–3500mg/g [30–350mg/mmol]), urine creatinine and a decrease450% from baseline,
and stable serum creatinine (change in creatinine o25%)
Relapse Proteinuria 43.5 g/d or 43500mg/g (4350mg/mmol) urine creatinine after complete remission has been obtained
Frequent relapse Not defined in adults
Steroid-dependent Two relapses during or within 2 weeks of completing steroid therapy
Steroid-resistant Persistence of proteinuria despite prednisone 1mg/kg/d or 2mg/kg every other day for 44 months
FSGS, focal segmental glomerulosclerosis; GFR, glomerular filtration rate.
aBoth definitions of partial remission have been used in the literature.
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6.4: Treatment for steroid-resistant FSGS
6.4.1: For steroid-resistant FSGS, we suggest that
cyclosporine at 3–5mg/kg/d in divided doses
be given for at least 4–6 months. (2B)
6.4.2: If there is a partial or complete remission,
we suggest continuing cyclosporine treatment
for at least 12 months, followed by a slow
taper. (2D)
6.4.3: We suggest that patients with steroid-resistant
FSGS, who do not tolerate cyclosporine, be
treated with a combination of mycophenolate
mofetil and high-dose dexamethasone. (2C)
BACKGROUND
There is no agreement in the literature regarding the duration
of prednisone therapy that defines steroid-resistance. Some
authors advise the use of alternative immunosuppressive
therapy after only 4–8 weeks of prednisone, whereas others
define resistance as persistent nephrotic syndrome after
4 months prednisone in a dose of 1 mg/kg/d.144,170,182,183
We suggest that prednisone be given for 4 months before
defining resistance to therapy.
RATIONALE
Cyclosporine is effective in inducing remission of proteinuria
in patients with steroid-resistant FSGS. Remissions can
develop slowly, and may take 3–6 months after start of
therapy.
K A partial remission provides a substantial outcome
benefit.
K Relapses are very frequent after withdrawal of cyclo-
sporine. More prolonged treatment may lead to more
persistent remissions. Relapses occur frequently when
using cyclosporine for a 6-month period. A longer
duration of therapy and slow tapering strategy in
cyclosporine-responsive patients can be used in FSGS
(Table 11) similar to that advised in adults with MCD.
K There is limited evidence to support the efficacy of other
regimens in patients with steroid-resistant proteinuria.
CNIs
Two RCTs have shown that cyclosporine is more effective
than no treatment in inducing remission of proteinuria in
FSGS with SRNS.110,184,185 In one of the two studies,
cyclosporine was combined with low-dose prednisone. These
are summarized in Online Suppl Tables 14–16. Remission in
the two studies occurred in 60% and 69%, but relapse after
cyclosporine withdrawal occurred in 69% and 61%, respec-
tively. An additional benefit to cyclosporine treatment was an
attenuated deterioration of kidney function in one study,
with doubling of SCr in 25% of treated vs. 52% of control
patients. An additional, but low-quality, controlled trial
(Online Suppl Tables 14–16) as well as various uncontrolled
studies have confirmed that treatment with cyclosporine
reduces proteinuria in patients with FSGS.141,186–189 These
observational studies reported remission rates of 10–75%.
The variation in reported remission rates may depend on the
definition of steroid resistance, the prior use of alkylating
agents, and the concomitant use of low-dose prednisone.
Remissions usually develop within 2–3 months, but may take
longer (4–6 months). All studies report high relapse rates
(60–80%). Patients who respond within 6 months to
cyclosporine can sometimes be maintained for periods of
years without untoward effects on kidney function; how-
ever, deterioration of kidney function may occur, even if
proteinuria has remitted.188 Deterioration of kidney function
is more likely in patients who use high-dose cyclosporine
(45.5 mg/kg/d), in patients with pre-existing reduced GFR
(o60 ml/min per 1.73 m2) and pre-existent tubulo-
interstitial fibrosis.144
There are no RCTs using tacrolimus. Uncontrolled studies
suggest that tacrolimus may be an alternative to cyclo-
sporine.181,190 Segarra et al.190 treated 25 patients with
cyclosporine-resistant or cyclosporine-dependent FSGS.
Tacrolimus was used in a dose of 0.15 mg/kg/d and targeted
to trough levels of 5–10 mg/l; there was a 100% remission rate
in the cyclosporine-dependent patients, 100% in patients
who had developed resistance to cyclosporine, and 62% in
patients with resistance to the initial treatment with
cyclosporine. These limited observational studies suggest
tacrolimus may be an alternative in patients intolerant of
cyclosporine.
Table 11 | Treatment schedules
Drug and dosing scheme
Initial treatment
Prednisone*
1mg/kg/d in patients (up to a maximum of 80mg/d) or alternate-day
prednisone 2mg/kg (up to 120mg) for at least 4 weeks and for a
maximum of 4 months; in case of a complete remission, taper
prednisone: e.g., reduce dose by 10mg per 2 weeks down to
0.15mg/kg/d, then taper dose every 2–4 weeks by 2.5mg.
In SR FSGS patients, taper off prednisone over 6 weeks.
Therapy for SR FSGS
Cyclosporine
3–5mg/kg/d: in two divided doses (initial target levels 125–175 ng/ml
[104–146 nmol/l]); in case of a remission continue treatment for 1 year
then try to slowly taper cyclosporine: reduce cyclosporine dose by 25%
every 2 months. If no remission by 6 months, discontinue cyclosporine
treatment.
Or
Tacrolimus
0.1–0.2mg/kg/d in two divided doses (initial target levels 5–10 ng/ml
[6–12 nmol/l]); in case of remission see advice for cyclosporine.
And
Prednisone
0.15mg/kg/d for 4–6 months, then taper off over 4–8 weeks.
FSGS, Focal segmental glomerulosclerosis; SR, steroid-resistant.
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Other Immunosuppressive Agents
A recent RCT compared cyclosporine to the combination of
MMF and high-dose dexamethasone in children and young
adults with steroid-resistant FSGS.111 There was no statistically
significant difference in remission rates. The study was largely
underpowered, and inferiority of the MMF regimen could not
be excluded. Case reports and small observational studies have
reported response to alkylating agents, sirolimus, and ritux-
imab, but there is insufficient evidence to support the use of
any of these agents in patients with steroid-resistant FSGS.
RESEARCH RECOMMENDATIONS
K An RCT is needed of corticosteroid therapy at presenta-
tion compared to delayed corticosteroid therapy.
K An RCT is needed to evaluate the comparative efficacy of
CNIs, alkylating agents, and MMF in steroid-resistant FSGS.
K Validation studies are needed on the most recent
classification of FSGS152 to test its reproducibility, impact
on outcome, and capacity to predict response to cortico-
steroids and immunosuppressive agents.
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